Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes [1]. It is administered as a weekly subcutaneous injection [1].
How does dulaglutide work?
Dulaglutide mimics the action of the natural incretin hormone GLP-1 [1]. By activating GLP-1 receptors, it stimulates insulin secretion, reduces glucagon secretion, and slows gastric emptying, all of which help to lower blood glucose levels [1].
When did dulaglutide get approved?
Dulaglutide was first approved by the U.S. Food and Drug Administration (FDA) in September 2014 [2].
What is the difference between dulaglutide and other diabetes medications?
Dulaglutide is a GLP-1 receptor agonist, which differs from other classes of diabetes medications like metformin (a biguanide), sulfonylureas, or insulin [1][3]. GLP-1 receptor agonists like dulaglutide are associated with a lower risk of hypoglycemia compared to some other agents and can lead to weight loss [1]. It is also distinct from other GLP-1 receptor agonists, such as liraglutide or semaglutide, primarily in its dosing frequency and molecular structure [4].
What are the approved uses for dulaglutide?
In addition to type 2 diabetes, dulaglutide has also been approved to reduce the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors [1].
What are the common side effects of dulaglutide?
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and decreased appetite [1]. These gastrointestinal side effects are generally mild to moderate and tend to decrease over time [1].
What are the risks associated with dulaglutide?
Potential risks include a boxed warning for a possible increased risk of thyroid C-cell tumors, which has been observed in rodent studies, though the human relevance is not known [1]. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 [1]. Other serious side effects can include pancreatitis, gallbladder problems, and allergic reactions [1].
When does dulaglutide's patent protection expire?
Patent protection for drugs is complex and can involve multiple patents covering different aspects of the drug, such as its composition, formulation, and method of use [5]. Information on specific patent expiry dates for dulaglutide can be found on specialized patent tracking websites [5]. DrugPatentWatch.com provides detailed patent information for pharmaceuticals, including expiry dates and patent litigation [5].
What are the key competitors to dulaglutide?
Key competitors include other GLP-1 receptor agonists such as liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), and dulaglutide's predecessor, exenatide (Byetta, Bydureon) [4]. SGLT2 inhibitors and other classes of oral antidiabetic agents also compete in the type 2 diabetes market [3].
Can biosimilars of dulaglutide be developed?
As a biologic drug, dulaglutide is eligible for biosimilar development once its relevant patents and exclusivity periods expire [6]. Biosimilars are highly similar to the reference biologic product and have no clinically meaningful differences in terms of safety, purity, and potency [6].
What clinical trials have been conducted for dulaglutide?
Extensive clinical trials have evaluated dulaglutide's efficacy and safety in various populations of patients with type 2 diabetes. The REWIND trial, for instance, demonstrated its cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors [1].
How is dulaglutide supplied and what is the typical dosage?
Dulaglutide is supplied as a solution for subcutaneous injection in pre-filled pens [1]. The common dosage is 1.5 mg once weekly, with a 0.75 mg weekly dose also available for initiating treatment [1].
What is the typical cost of dulaglutide?
The cost of dulaglutide can vary significantly based on insurance coverage, pharmacy, and geographic location. Drug pricing information is often available through pharmaceutical manufacturer websites or pharmacy benefit managers [7].
Sources:
[1] https://www.drugpatentwatch.com/dulaglutide/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fdatakes-action-about-certain-diabetes-medications
[3] https://www.drugpatentwatch.com/blog/2023/04/17/types-of-diabetes-medications/
[4] https://www.drugpatentwatch.com/blog/2023/05/11/semaglutide-vs-liraglutide/
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/blog/2023/02/22/what-are-biosimilars/
[7] https://www.drugpatentwatch.com/blog/2023/06/20/understanding-drug-pricing/